Thomas Berger Michael Linnebank Heinz Wiendl (Hrsg.) 2013 1988 wurde die erste Phase-III-Studie mit Interferon beta-1b begonnen – revolutionär ob ihres Studiendesigns, welches den Standard für alle weiteren Phase-IIIStudien bei Multipler Sklerose (MS) bis zum heutigen Tag begründete, revolutionär aber auch wegen der nachfolgenden Zulassung von Interferon beta-1b. 1993 wurde Interferon beta-1b unter dem Namen Betaseron® bzw. Betaferon® in […]

P.N. Patsalos 2013 Since the publication of the fi rst edition of this book in July 2005, much has changed in the fi eld of antiepileptic drug (AED) interactions. Firstly, fi ve new AEDs have been licensed for clinical use (eslicarbazepine acetate, lacosamide, retigabine, ru fi namide, and stiripentol); and secondly there has been a surge of publications reporting on […]

Santosh A. Helekar Editor 2013 Dysfunction of motor, sensory, and cognitive aspects of speech and language forms a substantial component of the clinical presentation in neurological practice. It is frequently present in the most common neurological conditions such as stroke and Parkinson’s disease, as well as many other neurodegenerative diseases, and neurodevelopmental conditions such as autism spectrum disorders. Primary […]